Last reviewed · How we verify
Balance Tablet
Balance Tablet is a marketed formulation designed to support electrolyte and mineral balance, likely through provision of essential minerals and electrolytes.
Balance Tablet is a marketed formulation designed to support electrolyte and mineral balance, likely through provision of essential minerals and electrolytes. Used for Electrolyte imbalance or depletion, Mineral supplementation.
At a glance
| Generic name | Balance Tablet |
|---|---|
| Sponsor | General Committee of Teaching Hospitals and Institutes, Egypt |
| Drug class | Electrolyte/mineral supplement |
| Modality | Small molecule |
| Therapeutic area | Nutritional/Metabolic support |
| Phase | FDA-approved |
Mechanism of action
The drug appears to be a mineral and electrolyte supplement formulation intended to maintain or restore physiological electrolyte balance. Without access to the specific formulation details, the exact mechanism likely involves replacement or supplementation of key electrolytes such as potassium, sodium, magnesium, or calcium to support normal cellular and organ function.
Approved indications
- Electrolyte imbalance or depletion
- Mineral supplementation
Common side effects
- Gastrointestinal upset
- Nausea
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) (PHASE2, PHASE3)
- Primary Connections for Youth and Families (NA)
- A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body (PHASE1)
- The Effects of High-dose Vitamin B6 on Depression and Anxiety Symptoms (NA)
- "Intra-articular Hyaluronic Acid Injection for Accelerating Functional Recovery After Knee Arthroscopy" (NA)
- A Study to Test How BI 1819479 is Taken up and Processed by the Body (PHASE1)
- Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Balance Tablet CI brief — competitive landscape report
- Balance Tablet updates RSS · CI watch RSS
- General Committee of Teaching Hospitals and Institutes, Egypt portfolio CI